Evidence map›Paper›PMID 34668726›Full record

ArticleMicrobiology spectrum2021

Targeting Aryl Hydrocarbon Receptor Signaling Enhances Type I Interferon-Independent Resistance to Herpes Simplex Virus.

Jincheng Chen, Juan Liang, Hui Xu, Wenqi Liu, Shuyan Liu, Lian Duan, Fang Li, Zhaoqin Wang, Yingxia Liu, Brian McSharry and 2 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Seborrhoea Herpeticum: A distinct entity or mere coincidence.Indian dermatology online journal · 2025
    Article
  3. The role of the AHR in host-pathogen interactions.Nature reviews. Immunology · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jincheng Chen *Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
Juan Liang *National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Hui Xu *National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Wenqi Liu *National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Shuyan LiuNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Lian DuanNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Fang LiNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Zhaoqin WangNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Yingxia LiuNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.
Brian McSharryInfections, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-0473-2789
Carl G FengInfections, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Guoliang ZhangNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, The Third People's Hospital of Shenzhen, Southern University of Science and Technology, Shenzhen, China.ORCID 0000-0002-3617-5449
Southern University of Science and Technology · CNThe University of Sydney · AUJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcript factor that plays an important role in regulating immunity and cell differentiation. However, its role in cell-autonomous antiviral resistance has not been fully elucidated. Here, we show that interruption of AHR signaling in human cells by a chemical antagonist or genetic targeting led to significant reductions in the replication of herpes simplex virus 1 (HSV-1) and cytomegalovirus (CMV), revealing an unexpected proviral function of AHR. Interestingly, the enhanced viral control in the absence of AHR is independent of type I interferon (IFN) signaling. Together, these results reveal a previously unknown function of AHR in promoting viral replication

Indexed as

Herpes SimplexHerpesvirus 1, HumanHumansInterferon Type IReceptors, Aryl HydrocarbonSignal TransductionVirus ReplicationInterferon Type IReceptors, Aryl Hydrocarbonaryl hydrocarbon receptorherpes simplex virus 1type I interferonsviral replication

Identifiers

PMID34668726
PMCPMC8528105
OpenAlexW3206823057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.